en · de · es · fr · pt
thymosin-alpha-1-notes.peptides4800.com › News › Molecular Structure And Biological Background — Evidence Review

Molecular Structure And Biological Background — Evidence Review

By Editorial Desk · published 2025-08-16 · last reviewed 2025-10-04 · News

This is a working overview of prothymosin alpha, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.

Molecular Structure and Biological Background

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.

Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.

The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.

Background and Molecular Profile

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Chemical classSynthetic peptide, 28 residuesN-terminal fragment of prothymosin alpha
Molecular massAbout 3108 DaAcetylated form
Isoelectric pointNear 4.2Acidic peptide
AppearanceWhite to off-white lyophilized powderCommon supplied form
Typical storage-20 °C or below, drySolution stability is lower

Background, Structure, and Mechanism

Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Related pages on this site

Background and Mechanism of Action

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Further detail

A firm can design any number of channels they require to reach customers efficiently and effectively. Channels can be distinguished by the number of intermediaries between producer and consumer. If there are no intermediaries then this is known as a zero-level distribution system or direct marketing. A level one (sometimes called one-tier) channel has a single intermediary. A level two (alternatively a two-tier) channel has two intermediaries, and so on. This flow is typically represented as being manufacturer to retailer to consumer, but may involve other types of intermediaries. In practice, distribution systems for perishable goods tend to be shorter - direct or single intermediary, because of the need to reduce the time a product spends in transit or in storage. In other cases, distribution systems can become quite complex involving many levels and different types of intermediaries.

== Overdose == At doses over 20 or 30 mg orally, frightening hallucinations, as well as tachycardia, hypertension, and hyperthermia, may occur. The fatal dose of 2C-B in humans is unknown but its safety window is thought to be narrower than certain other psychedelics like LSD and psilocybin similarly to the case of mescaline. It was reported by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) that a psychologist had accidentally taken a 100 mg dose orally without apparent harm. There are three case reports of 2C-B intoxication in the scientific literature as of 2015 and no deaths have been attributed to 2C-B alone as of 2018.

Official website Ellen McLain at IMDb Ellen McLain speaking on YouTube, Anime Midwest 2011 convention The VŌC Podcast // Ellen McLain Interview (The voice of GLaDOS, The Administrator, Overwatch) on YouTube

Sources: en.wikipedia.org

Background from the literature

== Natural abundances of micronutrients == The natural abundance of elements is dependent on their atomic number based on the process of nucleosynthesis such that elements with higher atomic numbers are typically less abundant than elements with low atomic numbers. Most micronutrients are trace elements with high atomic numbers, meaning they exist naturally in low concentrations. Notable exceptions to this rule are boron (atomic no. 5), manganese (atomic no. 25), and iron (atomic no. 26). Primary producers are the main contributors to the incorporation of micronutrients into a community's chemical inventory. Consumers within an ecosystem are limited to the micronutrients in the tissue of the primary producers which they eat. Primary producers obtain their micronutrients from their surrounding abiotic environment and the recycling of organic matter in soils. For example, grasses take in iron from soils which animals rely upon for hemoglobin production.

==== Gene knockout studies ==== The large number of mouse compared to human FPR receptors makes it difficult to extrapolate human FPR1 functions based on genetic (e.g. gene knockout or forced overexpression) or other experimental manipulations of FPR receptors in mice. In any event, targeted disruption of the Fpr1 gene reduced the ability of mice to survive intravenous injection of the bacterial pathogen, listeria monocytogenes; disruption of the Fpr2 gene in mice produce a similar effect while disruption of both genes further lowered the survival of mice to the listeria challenge. The effect of these gene knockouts appeared due to faulty leukocyte function and other causes leading to a breakdown in the innate immune response. The functions of the human FPR1 receptor may be equivalent to the overlapping functions of the mouse Fpr1 and Fpr2 functions and therefore be critical in the defense against at least certain bacteria. Targeted disruption of FPR-rs1 produced a 33% reduction in the lifetime of mice; there was no specific pathology associated with this reduction.

The parasagittal (Greek πᾰρᾰ́ (pará), beside) or paramedian or sagittal planes (Latin sagitta, arrow), which include the median or midsagittal plane and divide the body into left and right (in reference to the subject and not the observer). The frontal or coronal plane (Latin corona, crown), which divide the body into front and back. The axial or horizontal or transverse plane (Latin trans, across; vetere, to turn), which is perpendicular to the other two planes. The transpyloric plane, the subcostal plane, and the transumbilical plane planes are also considered in the division of the torso into the quadrants and regions of the abdomen. The three main axes of a human are the left-right (or horizontal or frontal), the craniocaudal (or rostrocaudal, longitudinal, or cephalocaudal), and the anteroposterior (or dorsoventral or sagittal) axes. Other anatomical lines include the axillary lines, parasternal line, and scapular line.

Sources: en.wikipedia.org

Frequently asked questions

Is thymosin alpha-1 a naturally occurring hormone?

It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.

What is the difference between thymosin alpha-1 and other thymosins?

Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.

Does the peptide work by a single known mechanism?

No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.

How does thymosin alpha 1 differ from thymosin fraction 5?

Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.

Network